Stability engineering of antibody single-chain Fv fragments

Journal of Molecular Biology

Volumn 305, Issue 5, 2001, Pages 989-1010

  Wörn, Arne ^a   Plückthun, Andreas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antibody engineering; Protein folding; Protein stability; Recombinant antibodies; scFv fragments

Indexed keywords

RECOMBINANT ANTIBODY;

BIOTECHNOLOGY; DISULFIDE BOND; ENERGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN STABILITY; REVIEW;

EID: 0035793208     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2000.4265     Document Type: Review

References (137)

1. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment
2. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3
3. Intracellular immunization: Antibody targeting to subcellular compartments
4. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria
5. Single-chain antigen-binding proteins
6. Yeast surface display for screening combinatorial polypeptide libraries
7. Minimizing a binding domain from protein A
8. A simple model for proteins with interacting domains. Applications to scanning calorimetry data
9. Recognition of E. coli tryptophan synthase by single-chain Fv fragments: Comparison of PCR-cloning variants with the parental antibodies
10. L permutation
11. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment
12. The selection of intracellular antibodies
13. Therapeutic antibody fragments with prolonged in vivo half-lives
14. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv
15. Breakdown in the relationship between thermal and thermodynamic stability
16. Hydrogen exchange at equilibrium: A short cut for analysing protein-folding
17. Pharmacokinetics and biodistribution of genetically engineered antibodies
18. Antibody engineering
19. Absolute conservation of residue 6 of immunoglobulin heavy chain variable regions of class IIA is required for correct folding
20. Multimerization behavior of single-chain Fv variants for the tumor-binding antibody B72.3
21. Stabilization of antibody fragments in adverse environments
22. The use of fluorescence methods to monitor unfolding transitions in proteins
23. Crystallization of single-chain Fv proteins
24. Understanding and increasing protein stability
25. Core-directed protein design. I. An experimental method for selecting stable proteins from combinatorial libraries
26. Towards molecular farming in the future: Pichia pastoris-based production of single-chain antibody fragments
27. Beyond binding: Using phage display to select for structure, folding and enzymatic activity in proteins
28. Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface
29. Comparison of the amide proton exchange behavior of the rapidly formed folding intermediate and the native state of an antibody scFv fragment
30. A soluble immunoglobulin variable domain without a disulfide bridge: Construction, accumulation in the cytoplasm of E. coli, purification and physicochemical characterization
31. Contribution of the intramolecular disulfide bridge to the folding stability of REI(v), the variable domain of a human immunoglobulin kappa light chain
32. Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction
33. Molecular and cellular aspects of thiol-disulfide exchange
34. IMGT, the international ImMunoGeneTics database
35. A comparison of strategies to stabilize immunoglobulin Fy-fragments
36. The disulfide bonds in antibody variable domains: Effects on stability, folding in vitro, and functional expression in Escherichia coli
37. The role of the intrachain disulfide bond in the conformation and stability of the constant fragment of the immunoglobulin light chain
38. Conformation of the constant fragment of the immunoglobulin light chain: Effect of cleavage of the polypeptide chain and the disulfide bond
39. The progressive development of structure and stability during the equilibrium folding of the alpha subunit of tryptophan synthase from Escherichia coli
40. In vitro selection and evolution of functional proteins using ribosome display
41. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries
42. Antibodies from a designed library of fully synthetic genes were selected and evolved to subnanomolar affinities by using ribosome display
43. Exploiting antibody-based technologies to manage environmental pollution
44. Stability of a single-chain Fv antibody fragment when exposed to a high shear environment combined with air-liquid interfaces
45. Antibody-ribosome-mRNA (ARM), complexes as efficient selection particles for in vitro display and evolution of antibody combining sites
46. Nonrepetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology
47. "Diabodies": Small bivalent and bispecific antibody fragments
48. Recombinant antibody constructs in cancer therapy
49. High avidity scFv multimers: Diabodies and triabodies
50. A role of destabilizing amino acid replacements in light-chain amyloidosis
51. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digosin single-chain Fv analogue produced in Escherichia coli
52. Protein engineering of single-chain Fv analogs and fusion proteins
53. Medical applications of single-chain antibodies
54. Protein misassembly in vitro
55. Domain interactions in antibody Fv and scFv fragments: Effects on unfolding kinetics and equilibria
56. Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen
57. The ScFv fragment of the antibody hu4D5-8: Evidence for early premature domain interaction in refolding
58. Tailoring in vitro evolution for protein activity or stability
59. Replacing the complementarity-determining regions in a human antibody with those from a mouse
60. Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting
61. Selection for improved protein stability by phage display
62. Variable region heavy chain sequences
63. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity
64. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy
65. Engineering turns of a recombinant antibody improve its in vivo folding
66. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
67. Selectively infective phage (SIP): A mechanistic dissection of a novel method to select for protein-ligand interactions
68. Proteolytic selection for protein folding using filamentous bacteriophages
69. H domain lacking the disulfide bridge
70. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: A comparison of conjugation chemistries and compounds
71. Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy
72. In vitro folding and thermodynamic stability of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm
73. Expression of an antibody fragment at high levels in the bacterial cytoplasm
74. Protein interaction methods, toward an endgame
75. Denaturant m values and heat capacity changes: Relation to changes in accessible surface areas of protein unfolding
76. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: Improved in vivo folding and physical characterization of an engineered scFv fragment
77. L domain stability
78. Beta-turn propensities as paradigms for the analysis of structural motifs to engineer protein stability
79. Intrabody construction and expression. II. A synthetic catalytic Fv fragment
80. Determination and analysis of urea and guanidine hydrochloride denaturation curves
81. Measuring and Increasing protein stability
82. Measuring the conformational stability of a protein
83. Anatomy of the antibody molecule
84. Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli
85. The potential for enhanced tumor-localization by poly(ethylene glycol) modification of anti-CEA antibody
86. An in vivo, library-versus-library competition strategy for the selection of optimized protein-protein interactions
87. Monovalent and bivalent antibody fragments produced in Escherichia coli: Engineering, folding and antigen-binding
88. New protein engineering approaches to multivalent and bispecific antibody fragments
89. Producing antibodies in Escherichia coli: From PCR to fermentation
90. H: Consequences for thermodynamic stability and folding
91. Antibody scFv fragments without disulfide bonds made by molecular evolution
92. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains
93. A form of anti-Tac(Fv) which is both single-chain and disulfide-stabilized: Comparison with its single-chain and disulfide-stabilized homologs
94. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered Into conserved framework regions
95. Engineering Interchain disulfide bonds into conserved framework regions of Fv fragments: Improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv
96. Disulfide stabilization of antibody Fv: Computer predictions and experimental evaluation
97. Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments
98. Optimizing the stability of single-domain proteins by linker length and composition mutagenesis
99. HER2 Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug
100. Fluorescence spectroscopy
101. Stabilizing the subtilisin BPN' prodomain by phage display selection: How restrictive is the amino acid code for maximum protein stability?
102. Protein engineering from a bio-industrial point of view
103. A reversibly unfolding fragment of P22 tailspike protein with native structure: The isolated beta-helix domain
104. Engineering enzymes for stability
105. Expression of functional single-chain antibody against GA(24/19) in transgenic tobacco
106. Comparative thermodynamic analyses of the Fv, Fab* and Fab fragments of anti-dansyl mouse monoclonal antibody
107. Molecular stability of chicken and rabbit immunoglobulin-G
108. Selecting proteins with improved stability by a phage-based method
109. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli
110. Antibody production in plants
111. Reproducing the natural evolution of protein structural features with selectively infective phage (SIP) technology
112. Sequence statistics reliably predict stabilizing mutations in a protein domain
113. Rapid evolution of a protein in vitro by DNA shuffling
114. L hydrogen bonding interaction to scFv folding stability and refolding efficiency
115. Protein denaturation. C. Theoretical models for the mechanism of denaturation
116. A single-chain antibody fragment is functionally expressed in the cytoplasm of both Escherichia coli and transgenic plants
117. X-ray crystallography reveals stringent conservation of protein fold after removal of the only disulfide bridge from a stabilized immunoglobulin variable domain
118. Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems
119. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein
120. Selection of antibodies for intracellular function using a two-hybrid in vivo system
121. Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules
122. Unfolding and inactivation: Genetic and chemical approaches to the stabilization of T4 lysozyme and interferon-gamma against irreversible thermal denaturation
123. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability
124. Multivalent Fvs: Characterization of single-chain Fv oligomers and preparation of a bispecific Fv
125. The immunoglobulin superfamily, domains for cell surface recognition
126. Reduction in the amide hydrogen exchange rates of an anti-lysozyme Fv fragment due to formation of the Fv-lysozyme complex
127. High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-EGP-2 (Ep-CAM) scFv fragment
128. Humanized antibodies
129. Making antibodies by phage display technology
130. Intrabody construction and expression III: Engineering hyperstable V-H domains
131. H in single-chain antibody fragments, investigated with mutants engineered for stability
132. An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly
133. Different equilibrium stability behavior of scFv fragments: Identification, classification and improvement by protein engineering
134. Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors
135. Effects of substitutions of amino acids on the thermal stability of the Fv fragments of antibodies
136. Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond
137. Remodeling domain interfaces to enhance heterodimer formation